A way to make drugs for poor countries
A public-private venture with funding from the Bill and Melinda Gates Foundation is being used to test a potential malaria vaccine. The collaboration may provide a viable business model for developing drugs for poor countries. Megan Williams reports.
Employees of Gabonese pharmaceutical factory Sogafam collect pills at a plant in Owendo, Gabon. (Desirey Minkoh/AFP/Getty Images)
More on International, Africa, Health
TEXT OF STORY
Kai Ryssdal: Nearly a million people die of malaria every year, most of them young children in sub-Saharan Africa. A public-private venture that includes $200 million from the Gates Foundation is working on a vaccine. It's about to do its final tests. And if the vaccine works, the collaboration that produced it could offer a viable business model for developing drugs for poorer countries. Megan Williams reports now from Gabon, in central Africa.
MEGAN WILLIAMS: Dr. Maxime Agnandji peers into a microscope at the Albert Schweitzer Hospital lab in Lamberene, Gabon.
The 35-year-old who grew up in the country heads the research unit here, as part of the biggest medical trial ever held in Africa. A malaria vaccine test involving 16,000 kids and 11 different research centers across the continent.
MAXIME AGNANJDI: Basically I want to stay here to develop my career here.
Agnanjdi is one of the principal investigators for the final test of the vaccine, called RTSS. So far, it's been shown to cut the rate of severe malarial infection by half. Agnanjdi says it's not only exciting to work on a solution to a mainly African problem, but on a project that's changing the face of medical research in Africa.
AGNANJDI: Since the 10 last years there is improvement in training, to control diseases. I've met many, many doctors from different countries, all are from Africa. Young researchers from Africa.
The Gates foundation decided to invest in the malaria vaccine research after scientists at the drug company Glaxo-Smith-Kline showed it had real potential. But for big drug companies vaccines in Africa just aren't profitable. People are too poor to pay. Without the Gates funding, the malaria vaccine wouldn't have been developed.
Rip Ballou of the Gates Foundation has been part of the quest for a malaria vaccine for more than two decades.
RIP BALLOU: If you go back 20 years, most research being done in Africa was being done by Europeans and Americans who came here because there's all these disease challenges, fascinating problems. But there was no resources coming from the African host nations.
Unlike most drug trials in Africa, the bulk of the funding has been invested right here, in Africa. By building first-rate hospitals and labs and upgrading facilities and equipment to Western standards. And, of course, developing motivated scientists like DR. Maxime Agnandji.
BALLOU: You know, I think one of great things that's happened with this program over the last several years is that we've identified a whole cadre of really talented African investigators to do this.
If this last trial of the RTSS vaccine proves effective, then in a few years comes the next hurdle, making it affordable to the people who so desperately need it. Glaxo-Smith-Kline is contractually obliged by the Gates Foundation to set a ceiling on the price, but it can also make a profit. Joe Cohen is the Glaxo-Smith-Kline scientist who invented the vaccine. He insists low cost is a priority.
JOE COHEN: It makes sense. This malaria vaccine, in contrast to many other vaccines, is exclusively meant for African children. There is no other market for it. It would be crazy for us after 25 years of work on malaria vaccine to do anything that would prevent this vaccine from being accessible and to see this vaccine just sitting on a shelf.
In Lamberene, Gabon, I'm Megan Williams for Marketplace.
Comments
Comment | Refresh
From Chandigarh, IN, 08/27/2009
it is quite a good post and truly appreciate it....
06/05/2009
very good innovation.
From Providence, RI, 05/26/2009
Great story. It gave me hope that Glaxo-Smith-Kline's JOE COHEN said they'll sell the vaccine at an appropriate cost. Great PR potential and the right thing to do.
PLEASE: What was the song played at the end of the story. Thank you!
Post a Comment: Please be civil, brief and relevant.
Email addresses are never displayed, but they are required to confirm your comments. All comments are moderated. Marketplace reserves the right to edit any comments on this site and to read them on the air if they are extra-interesting. Please read the Comment Guidelines before posting.
You must be 13 or over to submit information to American Public Media. The information entered into this form will not be used to send unsolicited email and will not be sold to a third party. For more information see Terms and Conditions and Privacy Policy.